News

International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by

This 150th patent is a testament to our team’s ingenuity and dedication to serving the approximately 2.5 million US patients

Timothy Alexander of MyChesCo publishes article about Lungpacer’s upcoming research presentations at the American Thoracic Society (ATS) 2025 conference in

Exton, PA – April 28, 2025 – This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters

Sarah Huffman of Technical.ly publishes article about Lungpacer Medical’s rapid growth to support sales of its FDA-approved AeroPace® System, and

John George of the Philadelphia Business Journal publishes article about Lungpacer Medical’s recent hiring of a Chief Commercial Officer, Kevin

Timothy Alexander of MyChesCo publishes article about Lungpacer Medical hiring Kevin Kearney as CCO, to lead the commercialization effort of

Leah Mikulich at DELCO.TODAY publishes article about Lungpacer Medical’s anticipated growth for the commercial launch of its AeroPace® System after

Medical Buyer publishes article about Kevin Kearney joining Lungpacer Medical as CCO as the company moves to commercialize its first

Company Appoints Medical Device and Healthcare Industry Veteran with 20 Years of Experience Exton, PA – March 24, 2025 –

John George of the Philadelphia Business Journal publishes article about Lungpacer Medical’s recent hiring, with plans to double its workforce

Sean Whooley at MassDevice publishes article about Lungpacer Medical’s receipt of an FDA investigational device excemption (IDE) to begin a

Exton, PA – March 10, 2025 – Lungpacer Medical, a leading neurostimulation company committed to advancing therapies that assist patients

DeviceTalks Weekly publishes interview with Doug Evans about Lungpacer Medical’s technology.

Timothy Alexander of MyChesCo publishes article about the positive results of Lungpacer’s STIMULUS Phase 1 Clinical Trial, demonstrating improved heart

Sean Whooley at MassDevice publishes article about the exciting results of Lungpacer Medical’s Phase 1 STIMULUS clinical study.

Exton, PA – February 20, 2025 – Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free

Exton, PA – December 5, 2024 – Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free

[https://www.nature.com/articles/s43856-024-00662-0]: In critically ill patients, deep sedation and mechanical ventilation suppress the brain-diaphragm-lung axis and are associated with cognitive issues

AeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy designed for quicker liberation from mechanical ventilation FOR IMMEDIATE RELEASE

Dr. Bassi’s presentations focus on the positive effects of ventilating ARDS patients using transvenous diaphragm neurostimulation, showcasing the benefits of

Emerging evidence suggests that mechanical ventilation (the standard of care) may be one of the primary causes of brain injury

From LSI:  “Lungpacer Medical (hashtag#LSIUSA24 Innovator) has designed the AeroPace® System to stimulate the nerves that activate the diaphragm muscle

Awarded to a program that creates innovative uses for emerging technologies. Doug Evans on behalf of Lungpacer Medical Lungpacer Medical

The Pleural Pressure Working Group (PLUG) is an international network of physicians and investigators working on advanced monitoring of mechanical

Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence. Lungpacer is dedicated to natural breathing by developing minimally invasive technologies designed to help patients wean off mechanical ventilation and breathe on their own. The RESCUE 3 study is the third in a series of studies to support FDA and international regulatory approvals.

“On behalf of myself and the Lungpacer medical team we would like to express our deep appreciation for being selected

Greifswald University Hospital tests new method (Lungpacer® System) for weaning of respiratory patients Constanze Steinke Pressearbeit Universität Greifswald 07/10/2020 08:54

VANCOUVER, British Columbia, April 14, 2020 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced

An average of 14,000 pulmonary, critical care and sleep medicine clinicians and researchers from around the world attend the ATS

The Society of Critical Care Medicine (SCCM) is the largest non-profit medical organization dedicated to promoting excellence and consistency in

The inaugural ERS Respiratory Failure and Mechanical Ventilation conference gathered more than 400 delegates from 60 countries, representing a diverse

VANCOUVER, British Columbia, January 2020 Lungpacer Medical, Inc., announced the completion of enrollment and follow up in its RESCUE 2

VANCOUVER, British Columbia, December 2019 Lungpacer Medical, Inc. announced the publication of the RESCUE 2 Study Design Manuscript in the

Findings from ongoing preclinical research using Lungpacer’s novel phrenic nerve pacing technology was presented at the American Association for Respiratory

VANCOUVER, British Columbia, June 14, 2019 Lungpacer Medical, Inc., announced today the enrollment of the first subject in the RESCUE

VANCOUVER, British Columbia, May 2019 Lungpacer Medical, Inc. announced that two abstracts were presented by colleagues at the University of

The ongoing preclinical research using Lungpacer’s novel phrenic nerve pacing technology was well represented at the 2019 American Thoracic Society

Lungpacer Medical, Inc., CEO Doug Evans presented preclinical and clinical research on Lungpacer’s novel phrenic nerve pacing technology at the

VANCOUVER, British Columbia, February 22, 2019 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced

Doug Evans, CEO of Lungpacer Medical, Inc., presented at The MedTech Conference in Philadelphia, PA. Sponsored by AdvaMed, The MedTech

Doug Evans, CEO of Lungpacer Medical, Inc., presented at the Wilson Sonsini Goodrich & Rosati 2018 Medical Conference in San

BURNABY, British Columbia, June 2018 Lungpacer Medical, Inc. was selected out of over 700 applicants to participate in the 2018

The top-ranked American Journal of Respiratory and Critical Care Medicine has published on-line a pre-clinical research study demonstrating  that the Lungpacer therapy mitigated ventilator-induced diaphragm atrophy in pigs that were sedated and ventilated in ICU-like conditions for 60 hours.

BURNABY, British Columbia, May 2018 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today

This multidisciplinary conference attracts pulmonary and critical care clinicians from around the world.  Liz Rohrs presented her preclinical work, which

Lungpacer Medical Inc. was invited to present at the inaugural RIS meeting in San Francisco, CA.  The Respiratory Innovation Summit

BURNABY, British Columbia, January 2018 Lungpacer Medical, Inc., announced the completion of enrollment into the RESCUE 1 feasibility study. This

BURNABY, British Columbia, January 2018 Lungpacer Medical, Inc. has opened its US headquarters in Exton, PA, with the corporate headquarters

BURNABY, British Columbia, 29 September 2017 Lungpacer Medical, Inc., announced today that the first subject has been enrolled in the

BURNABY, British Columbia, July 2017 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today

BURNABY, British Columbia, 20 June 2017 Lungpacer Medical, Inc., announced today that the first subject has been enrolled in the

BURNABY, British Columbia, February 2017 Lungpacer Medical, Inc., announced today that the findings from preclinical work have been published in

Burnaby, British Columbia, Canada – May 11, 2016 – Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that it has received Expedited Access Pathway (EAP) designation from the U.S. Food and Drug Administration (FDA).

BURNABY, British Columbia, May 2016 Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today

Lungpacer Medical, Inc. was invited to present at the 2016 Innovation Summit in Dublin, Ireland, the leading medical technology investment

BURNABY, British Columbia, Oct. 21, 2015 /PRNewswire/ — Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today the enrollment of the first patients in the Phrenic ACtivation for Enhanced Respiration (PACER) early feasibility trial.

Ready to Rocket is a unique business recognition list that profiles British Columbia technology companies with the greatest potential for revenue growth.

SFU spinout Lungpacer Medical Inc. welcomed nearly 100 guests on Dec. 11 to its new 6,500-sq.-ft. Burnaby premises, which are 3 1/2

Dr. Steve Reynolds, head of Critical Care and infectious diseases specialist at Royal Columbian Hospital, and Dr. Andy Hoffer, founder of Lungpacer Medical Inc., are collaborating to improve how intensive care units provide respiratory support for their sickest patients.

Lungpacer Medical Inc. takes silver for its Lungpacer Diaphragm Pacing System at the World’s Best Technology Showcase (WBTS), San Diego on October 26, 2012.

Lungpacer Medical Inc., has won the BC Technology Industry Association’s 2012 award for the Most Promising Pre-Commercial Technology.

Lungpacer showcased by RHI at Interdependence 2012 Global SCI Conference

VANCOUVER, BC, May 2, 2012 – Today the BC Technology Industry Association (BCTIA) announced the finalists for the 2012 Technology Impact Awards (TIAs).